Engineered to behave like a cell.

Biologics are real cells — and that’s precisely the problem. Donor-derived controls expire when donors become unavailable, change between lots, and carry the biological variability you’re trying to measure out of your assay. Every new donor pool means re-qualification. Every re-qualification means lost time and lost comparability to prior data.

You’re not controlling your assay. You’re managing a supply chain for living material that was never designed to be a standard.

Real cells also come with immunogenicity risks, restricted shipping conditions, and shelf lives measured in days. You build your assay around them, and then they’re gone.

Polystyrene beads are uniform and stable — for measuring a polystyrene bead. They have the wrong refractive index, wrong scatter signature, and wrong surface chemistry for standing in for a cell. When you use a polystyrene bead as a cellular control, you’re calibrating to an artifact.

Laser scatter and fluorescence signals that look fine on a bead can mask real population shifts in your actual cells — exactly the errors you need your controls to catch. In spectral and high-parameter cytometry, this gap becomes a source of systematic error, not just imprecision.

UltraComp beads solve one problem — capturing antibody — and introduce another. Their physical properties don’t match the cells in your panel. UltraComp particles have different autofluorescence, different scatter, and different spectral emission profiles than human cells.

Compensation matrices built from UltraComp work adequately in simple panels, but as panel complexity grows and instruments multiply, the mismatch compounds. Cross-site studies using UltraComp-derived compensation matrices drift. Lot-to-lot variation in antibody capture efficiency adds another variable.

UltraComp was an improvement over stained cells for compensation capture. It was never designed to be a cellular reference standard. Using it as one is a choice with a cost.